

# ForPatients

by Roche

Non-Small Cell Lung Cancer (NSCLC)

## A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

**Trial Status**  
Completed

**Trial Runs In**  
19 Countries

**Trial Identifier**  
NCT02409342 2014-003083-21  
GO29431

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This randomized, open-label study will evaluate the efficacy and safety of atezolizumab compared with chemotherapy consisting of a platinum agent (cisplatin or carboplatin per investigator discretion) combined with either pemetrexed (non-squamous disease) or gemcitabine (squamous disease) in programmed death-ligand 1 (PD-L1)-selected, chemotherapy-naive participants with Stage IV Non-Squamous or Squamous NSCLC.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT02409342 2014-003083-21 GO29431**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
>= 18 Years

**Healthy Volunteers**  
No

---